Advanced In Vitro Cell Technologies

About Advanced In Vitro Cell Technologies

Advanced In Vitro Cell Technologies SL, operating as Advancell, was established in 2001 and is headquartered in Barcelona, Spain. The company operates as a biotechnology firm with a focus on nanomedicine, specializing in the discovery of new applications for existing molecules and the development of related drugs, services, and reagents. Advancell is structured into three main units: an Alternative Testing unit, a Nanosystems unit, and a Therapeutics unit. The business model is centered on leveraging discoveries from academic environments, which are then improved, developed, and either licensed to third parties or brought to market directly.

The Alternative Testing unit focuses on improving biotech, pharmaceutical, and cosmetic developments by applying in vitro methods that have regulatory and predictive value. This division provides ADME-Tox services for the R&D departments of pharmaceutical and biotech companies, as well as CROs, conducting assays for in vitro absorption, distribution, metabolism, and toxicity under FDA guidelines and GLP standards. It also offers customized research and scientific consulting to the cosmetic and chemical industries for evaluating the in vitro safety and efficacy of raw materials and finished products. The Nanosystems unit is dedicated to developing drug delivery systems based on the company's proprietary nanosystems technology. Finally, the Therapeutics unit is responsible for developing Advancell's own portfolio of new drugs, originating from discoveries within the academic world.

Advancell creates and markets in vitro cell models with both regulatory and predictive capabilities. These cell-based models and assay kits are used by European customers for customized research and internal projects, offering a cost-effective alternative to in vivo studies by generating significant data in a short timeframe. The company's services include research services, safety assessments of cosmetic ingredients and final products, and toxicological evaluations.